In summary, most studies suggest that P2Y12 inhibitor monotherapy lowers MI risk; however, findings for stroke, bleeding, and mortality remain inconsistent [8, 9, 11, 15, 25, 22–24]. This evidence concerns the gene P2RY12 and Stroke.